The DUSP23 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population in which the DUSP23 gene has been disrupted, generating a loss-of-function model for investigating dual-specificity phosphatase functions in human cancer cells. This polyclonal product is designed for researchers seeking a genetically heterogeneous knockout background to study DUSP23-mediated dephosphorylation events within the mitogen-activated protein kinase (MAPK) pathway and focal adhesion dynamics. By abolishing functional DUSP23 expression, these cells enable dissection of the phosphatase’s role as a negative regulator of extracellular signal-regulated kinase 1/2 (ERK1/2) signaling and as a modulator of cell adhesion and migration.
HeLa cells, derived from a human cervical adenocarcinoma, serve as an established model for studying oncogenic signaling and tumor cell behavior. These immortalized epithelial cells harbor integrated human papillomavirus (HPV-18) genomic sequences and are characterized by robust proliferation and well-defined responses to growth factors, cytokines, and extracellular matrix cues. The HeLa background provides a relevant context for examining DUSP23 function in a cervical cancer setting, particularly given the cell line’s documented activation of MAPK cascades and its utility in migration and invasion studies.
DUSP23 encodes a dual-specificity phosphatase targeting phosphotyrosine and phosphothreonine residues, with key substrates active ERK2 and the focal adhesion kinase (FAK). DUSP23 acts downstream of receptor tyrosine kinases such as EGFR and FGFR upon stimulation by epidermal growth factor (EGF), directly interacting with ERK2, FAK, Grb2, and SOS1 to terminate signal propagation. Through dephosphorylation of cortactin and paxillin, it also modulates cytoskeletal reorganization and cell motility. Integrated with signals from oxidative stress and adhesion receptors, DUSP23 impacts effectors including ERK1/2, FAK, p38 MAPK, and p130Cas, serving as a convergence point for attenuating both proliferative and migratory cues.
In HeLa cells, DUSP23 loss is expected to relieve negative regulation of ERK1/2 and FAK phosphorylation, enhancing MAPK output and focal adhesion turnover. This dysregulation may promote sustained ERK activation, altered cell?Csubstrate interactions, and increased migratory potential??hallmarks of metastatic progression. The polyclonal nature of the knockout population allows analysis of phenotypic heterogeneity arising from stochastic gene disruption, better mimicking genetic variation in tumor populations. Consequently, this model provides a powerful tool to explore how DUSP23 loss contributes to oncogenic transformation and to screen for compounds that modulate MAPK-dependent tumor phenotypes.
Typical experimental applications include western blotting for phospho-ERK1/2 and phospho-FAK to assess signaling hyperactivity, RT?qPCR to confirm DUSP23 transcript ablation, transwell migration and invasion assays to measure functional consequences, and immunofluorescence staining for focal adhesion proteins (e.g., paxillin, cortactin) to visualize adhesion complex dynamics. Co?immunoprecipitation can be employed to map altered protein interaction networks in the absence of DUSP23. These cells are suitable for cancer cell signaling studies, MAPK pathway dissection, tumor suppressor investigations, and phosphatase activity profiling. For more information regarding this polyclonal knockout model, please contact Ascent Research.
